Z-FA-FMK

Research use only, not for human use.

Z-FA-FMK can irreversibly inhibit cysteine protease and also inhibit effector caspases.

Z-FA-FMK can irreversibly inhibit cysteine protease and also inhibit effector caspases.

Z-FA-FMK ((1S)-Z-FA-FMK; 5-100 μM; 1 h; Jurkat cells) reduces levels of DEVDase activity and DNA fragmentation. Z-FA-FMK inhibits the externalization of phosphatidylserine induced by either MX2870-1 or MX781. Z-FA-FMK (100 μM; 1 h; Jurkat cells) inhibits apoptosis. Z-FA-FMK inhibited the induction of DEVDase activity not only by the RRMs but also by other apoptotic insults, including etoposide-, ceramide-, and CD95/Fas receptor-mediated pathways.Z-FA-FMK (0-100 μM; 1 h; Jurkat cells) inhibits caspases 2, -3, -6, and -7 activity through repressed induction of DEVDase activity in Jurkat cells. Z-FA-FMK (0-20 μM; 48 h; HT1080 and mouse embryonic stem cells) blocks reoviral replication and cures cells of a persistent infection with reovirus in vitro.Z-FA-FMK (20 μM; 48 h; HT1080 cells) induces defects in reoviral maturation.

Z-FA-FMK (1 mg/kg; intratumor injection; every 2 d, for 27 d; SCID mice with HT1080 xenograft) blocks reovirus infection in vivo.Z-FA-FMK (8 mg/kg; i.v.; every 2 d, once; male BALB/c mice) markedly lessens the degree of impairment seen in D-GalN/TNF-α-induced kidney injury. Animal Model:SCID mice with HT1080 xenograft (6-8 weeks)Dosage:1 mg/kg Administration:Intratumor injection; every 2 days, for 27 daysResult:Blocked reovirus replication activity in both tumor and heart tissues.Animal Model:Male BALB/c mice Dosage:8 mg/kg Administration:Intravenous injection; once, 1 hour later, intraperitoneal injection D-GalN (700 mg/kg) and TNF-α (15 μg/kg).Result:Decreased in the D-GalN/TNF-α-induced degenerative changes.Decreased in the number of activated caspase-3-positive tubular epithelial cell.Increased in kidney GSH levels, CAT, SOD and GPx activities and decreased in kidney LPO levels, LDH activity, serum AST and ALT activities, uric acid, and urea levels were determined.

——

Others

Other Targets

Cysteine protease

Others-Field

——

197855-65-5

386.42

C21H23FN2O4

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (646.96 mM)

CC(C(=O)CF)NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years